Dechert advised ARCHIMED, a leading international private equity firm focused on the healthcare sector, on its investment in Ceva Santé Animale. Ceva Santé Animale is a global leader in animal health, having achieved a turnover of €1.77 billion in 2024.
This investment marks the 6th LBO transaction for Ceva Santé Animale. ARCHIMED is joining the capital of Ceva Santé Animale, alongside the group's longstanding shareholders, including Temasek, Téthys, Mérieux Equity Partners, PSP, EMZ, CGC and Sagard.
The Dechert team that advised ARCHIMED included partner Alain Decombe along with associates Vianney Toulouse and Mathilde Duchamp on transactional aspects; partner Sabina Comis along with associates Etienne Bimbeau, Antoine Pian and Pierre-Emmanuel Floc’h on tax, structuring and fundraising matters; and national partner Thibault Meiers and associate Maëlle Chausse on labor and data protection matters.
About Dechert
Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. Our nearly 1000 lawyers across 16 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.
Dechert’s Paris office is a key component of the firm's strategy in Europe and is active in antitrust/competition and European law, corporate/M&A, financial services & asset management, financing, intellectual property, labor and employment, litigation and compliance, regulatory and tax.
Dechert’s life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments. Read more »
Related Professionals
